Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare
Diseases of the Integumentary System
What is the purpose of this trial?
To investigate the ability of tofacitinib, a Janus kinase (JAK) inhibitor, to treat patients with cutaneous sarcoidosis and granuloma annulare during 6 months of therapy.
- Ages18 years and older
- Trial withPfizer Inc., U.S. Pharmaceuticals Group
- Start Date04/07/2019
- End Date08/30/2020
- Last Updated07/15/2019
- Study HIC#2000023910